Elotuzumab (anti-SLAMF7)

製品コード：A2034         Batch: A203401

印刷

Elotuzumab (anti-SLAMF7, BMS-901608, PDL063, HuLuc63) is a humanized monoclonal antibody that binds human signaling lymphocytic activation molecule F7 (hSLAMF7, also known as CS1, CD319, or CRACC). Elotuzumab shows a dual mechanism of action that includes the direct activation of natural killer (NK) cells and the induction of NK cell–mediated antibody-dependent cellular cytotoxicity.

製品説明

CAS No. 915296-00-3
Formulation PBS Buffer, PH 7.4
Isotype Human IgG1, κ
Source CHO cells
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles.
Shipping Shipped under low temperature conditions
Purity 98%
Protein concentration 4.7 mg/ml
Endotoxin Level <1 EU/mg

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Design of sensitive monospecific and bispecific synthetic chimeric T cell receptors for cancer therapy [ Nat Cancer, 2025, 10.1038/s43018-025-00927-0] PubMed: 40097658
Epigenetic regulation of CD38/CD48 by KDM6A mediates NK cell response in multiple myeloma [ Nat Commun, 2024, 15(1):1367] PubMed: 38355622
CS1 Expression Pattern in NK Cells and Correlated Factors in Plasma Cell dyscrasias: Implications for Elotuzumab Therapy and CAR-T Efficacy [ J Cancer, 2024, 15(10):3065-3075] PubMed: 38706917

人間や獣医の診断であるか治療的な使用のためにでない。